Cargando…

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study

SIMPLE SUMMARY: Immune-checkpoint inhibitors have only been studied in clinical trials for second-line and now first-line malignant pleural mesothelioma. Sometimes, results found in clinical trials do not translate to real-life settings. We aim to study second-line and onward nivolumab in malignant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assié, Jean-Baptiste, Crépin, Florian, Grolleau, Emmanuel, Canellas, Anthony, Geier, Margaux, Grébert-Manuardi, Aude, Akkache, Nabila, Renault, Aldo, Hauss, Pierre-Alexandre, Sabatini, Marielle, Bonnefoy, Valentine, Cortot, Alexis, Wislez, Marie, Gauvain, Clément, Chouaïd, Christos, Scherpereel, Arnaud, Monnet, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946798/ https://www.ncbi.nlm.nih.gov/pubmed/35326648 http://dx.doi.org/10.3390/cancers14061498

Ejemplares similares

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
por: Chouaid, Christos, et al.
Publicado: (2018)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC
por: Roborel de Climens, Ferréol, et al.
Publicado: (2021)

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
por: Quetel, Lisa, et al.
Publicado: (2020)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
por: Meiller, Clément, et al.
Publicado: (2021)

Physician Empathy Interacts with Breaking Bad News in Predicting Lung Cancer and Pleural Mesothelioma Patient Survival: Timing May Be Crucial
por: Lelorain, Sophie, et al.
Publicado: (2018)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
por: Assié, Jean-Baptiste, et al.
Publicado: (2020)

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
por: Assié, Jean-Baptiste, et al.
Publicado: (2023)

Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis
por: Gendarme, Sébastien, et al.
Publicado: (2021)

Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients
por: Raiko, Irina, et al.
Publicado: (2010)

Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
por: Willems, Mégane, et al.
Publicado: (2023)

HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells
por: Hoyos, Clotilde, et al.
Publicado: (2022)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2022)

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study
por: Ezzedine, Rémy, et al.
Publicado: (2023)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study
por: Decavèle, Maxens, et al.
Publicado: (2022)

Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
por: Marchal, Marine, et al.
Publicado: (2023)

Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer
por: Ardin, Camille, et al.
Publicado: (2023)

General seizures revealing macro-adenomas secreting prolactin or prolactin and growth hormone in men
por: Chentli, Farida, et al.
Publicado: (2014)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study
por: Olivier, Cecile, et al.
Publicado: (2018)

Mesothelioma
por: Rao, Nagarjun, et al.
Publicado: (2022)

Mesothelioma
por: Deraco, Marcello
Publicado: (2021)

Suppurative meningitis: A life-threatening complication in male macroprolactinomas
por: Chentli, Farida, et al.
Publicado: (2013)

Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis
por: Smeele, Patrick, et al.
Publicado: (2018)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
por: Domblides, Maël, et al.
Publicado: (2021)

Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
por: Bourbonne, Vincent, et al.
Publicado: (2022)

Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy
por: Lucia, François, et al.
Publicado: (2022)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Peritoneal mesothelioma.
por: Kealey, W. D., et al.
Publicado: (1993)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_40oq5q63et1vcg3m3pg4b1iqao